TimothySFenskeMDMS

Oncology • Milwaukee, WI

Hematologic Oncology

Professor of Medicine

Join to view full profile

Dr. Fenske is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Fenske's full profile

Already have an account?

Office
Froedtert / MCW Clinical Cancer Center
9200 West Wisconsin Avenue
Milwaukee, WI 53226
Phone+1 414-805-4633

Fax+1 414-805-4606
Is this information wrong?

Education & Training

Washington University/B-JH/SLCH ConsortiumFellowship, Hematology and Medical Oncology, 2002 - 2005
University of Wisconsin Hospitals and ClinicsResidency, Internal Medicine, 1999 - 2002
University of Wisconsin School of Medicine & Public HealthClass of 1999

Certifications & Licensure

WI State Medical License 2000 - 2025
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

Murphy Award for Clinical Excellence Medical College of WI, Dept of Medicine, 2012
CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013

Clinical Trials

Rituxan/BEAM vs Bexxar/BEAM in Autologous Hematopoietic Stem Cell Transplant for Non-Hodgkin's Lymphoma (BMTCTN0401) Start of enrollment: 2005 Dec 01
Completed
Phase 3
Blood Stem Cell Transplant With Low Dose Chemotherapy for Relapsed Follicular Non-Hodgkin's Lymphoma (BMT CTN 0701) Start of enrollment: 2009 Apr 01
Completed
Phase 2
Combination Chemotherapy in Treating Patients With Non-Metastatic Extracranial Ewing Sarcoma Start of enrollment: 2010 Nov 22
Active, not recruiting
Phase 3
Study of Velcade and Temsirolimus for Relapsed or Refractory Non-Hodgkin Lymphoma Start of enrollment: 2011 Feb 01
Completed
Phase 2
Efficacy and Safety of Idelalisib (GS-1101) in Combination With Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas Start of enrollment: 2013 Jan 16
Terminated
Phase 3
Efficacy and Safety of Idelalisib (GS-1101) in Combination With Bendamustine and Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas Start of enrollment: 2013 Jan 02
Terminated
Phase 3
Rituximab and Combination Chemotherapy With or Without Lenalidomide in Treating Patients With Newly Diagnosed Stage II-IV Diffuse Large B Cell Lymphoma Start of enrollment: 2013 Aug 27
Active, not recruiting
Phase 2
Brentuximab Vedotin and Nivolumab With or Without Ipilimumab in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma Start of enrollment: 2014 Mar 07
Suspended
Phase 1, Phase 2
Rituximab With or Without Stem Cell Transplant in Treating Patients With Minimal Residual Disease-Negative Mantle Cell Lymphoma in First Complete Remission Start of enrollment: 2018 Mar 06
Recruiting
Phase 3
Safety and Preliminary Efficacy of JBH492 Monotherapy in Patients With CLL and NHL Start of enrollment: 2020 Sep 07
Active, not recruiting
Phase 1
Join now to see all

Publications & Presentations

PubMed

A phase 1-2 trial of DA-EPOCH-R plus ixazomib for MYC-aberrant lymphoid malignancies: the DACIPHOR regimen.
Karmali, R., Reem Karmali, Carlos Galvez, Mehdi Hamadani, Leo Gordon, Jane Winter, Shuo Ma, Valerie Nelson, Timothy S Fenske, Nirav N Shah, Deepa Jagadeesh, Andreas Kl...> ;Blood Advances. 2024 Apr 9
2 citations
Efficacy of Multiple SARS-CoV-2 Vaccine Doses in Patients with B Cell Hematologic Malignancies Receiving Chimeric Antigen Receptor T Cell Therapy: A Contemporary Cohor...
Muhammad Bilal Abid, Micah Rubin, Aniko Szabo, Walter Longo, Timothy S Fenske, Cole McCoy, Aaron Lorge, Sameem Abedin, Anita D'Souza, Binod Dhakal, Nirav N Shah, Mehdi...> ;Transplantation and Cellular Therapy. 2024 Mar 1
Severity and organ distribution of chronic graft-versus-host disease with posttransplant cyclophosphamide-based versus methotrexate/calcineurin inhibitor-based allogen...
Chhabra, S., Jerkins, J., Monahan, K., Szabo, A., Shah, N., Abedin, S., Runaas, L., Fenske, T., Pasquini, M., Shaw, B., Drobyski, W., Saber, W., D'Souza, A., Dhakal, B...> ;Bone Marrow Transplantation. 2024 Mar 1
Outcomes of patients with blastoid and pleomorphic variant mantle cell lymphoma.
Gerson, J., Handorf, E., Villa, D., Gerrie, A., Chapani, P., Li, S., Medeiros, L., Wang, M., Cohen, J., Churnetski, M., Hill, B., Sawalha, Y., Hernandez-Ilizaliturri, ...> ;Blood Advances. 2023 Dec 26
Immunoglobulin High Throughput Sequencing (Ig-HTS) Minimal Residual Disease (MRD) Analysis is an Effective Surveillance Tool in Patients With Mantle Cell Lymphoma.
Alexandra Rezazadeh, Julie Pruett, Amy Detzner, Natasha Edwin, Mehdi Hamadani, Nirav N Shah, Timothy S Fenske> ;Clinical Lymphoma, Myeloma & Leukemia. 2024 Apr 1
Outcomes of limited stage primary bone diffuse large B-cell lymphoma in the rituximab era: a multicenter, retrospective study.
Barr, P. M., Barr, P. M., Barr, P. M., Karmali, R., Alexandra Rezazadeh, Aniko Szabo, Arushi Khurana, David J Inwards, Matthew A Lunning, Nancy L Bartlett, Paolo F Cai...> ;Haematologica. 2023 Oct 19
A phase II study of interrupted and continuous dose lenalidomide in relapsed/refractory Hodgkin lymphoma.
Todd A Fehniger, Marcus P Watkins, Nkiruka Ezenwajiaku, Fei Wan, David D Hurd, Amanda F Cashen, Kristie A Blum, Andre Goy, Timothy S Fenske, Nina D Wagner-Johnston, Ke...> ;Haematologica. 2024 Mar 1
3 citations
Impact of diagnosis to treatment interval in patients with newly diagnosed mantle cell lymphoma.
Narendranath Epperla, Jeffrey Switchenko, Veronika Bachanova, James N Gerson, Stefan K Barta, Max J Gordon, Alexey V Danilov, Natalie S Grover, Stephanie Mathews, Made...> ;Blood Advances. 2023 Jun 13
Salvage polatuzumab and allogeneic transplant rescue patients with B-cell lymphoma failing CAR T-cell therapy.
Morgan Maring, Aniko Szabo, Timothy S Fenske, Mehdi Hamadani, Nirav N Shah, Furqan, F.> ;Blood Advances. 2023 Jun 13
Corrigendum to 'Ixazomib for chronic Graft-Versus-Host Disease prophylaxis following allogeneic hematopoietic cell transplantation' [Biology of Blood and Marrow Transp...
Saurabh Chhabra, Alexis Visotcky, Marcelo C Pasquini, Fenlu Zhu, Xiaoying Tang, Mei-Jie Zhang, Robert Thompson, Sameem Abedin, Anita D'Souza, Binod Dhakal, William R D...> ;Transplantation and Cellular Therapy. 2022 Oct 1
2 citations
Frontline Therapy in Mantle Cell Lymphoma: When Clinical Trial and Real-World Data Collide.
Timothy S Fenske> ;Journal of Clinical Oncology. 2023 Jan 20
5 citations
Long-term outcomes and predictors of early response, late relapse, and survival for patients treated with bispecific LV20.19 CAR T-cells.
Joanna C Zurko, Timothy S Fenske, Bryon D Johnson, Daniel Bucklan, Aniko Szabo, Huiqing Xu, Katherine Chaney, Mehdi Hamadani, Parameswaran Hari, Nirav N Shah> ;American Journal of Hematology. 2022 Dec 1
4 citations
Impact of Chronic Kidney Disease and Acute Kidney Injury on Safety and Outcomes of CAR T-Cell Therapy in Lymphoma Patients.
Gulrayz Ahmed, Bhavna Bhasin-Chhabra, Aniko Szabo, Nirav N Shah, Walter Longo, Binod Dhakal, Saurabh Chhabra, Anita D'Souza, Timothy S Fenske, Mehdi Hamadani> ;Clinical Lymphoma, Myeloma & Leukemia. 2022 Nov 1
1 citations
Treatment of Mantle Cell Lymphoma in the Frontline Setting: Are We Ready for a Risk-Adapted Approach?
Timothy S Fenske, Hammons, L.> ;Journal of Personalized Medicine. 2022 Jul 13
2 citations
Shorter Interval between Treatment and COVID Immunization Is Associated With Poor Seroconversion in Patients with Hematological Malignancies.
Meera Mohan, Sneha Nagavally, Nirav N Shah N, Laura Michaelis, Saurabh Chhabra, Anita D Souza, Sameem Abedin, Lyndsey Runaas, Guru Subramanian Guru Murthy, Walter Long...> ;Clinical Lymphoma, Myeloma & Leukemia. 2022 Jul 1
10 citations
Use of Early Intrathecal Therapy to Manage High-Grade Immune Effector Cell-Associated Neurotoxicity Syndrome.
Joanna C Zurko, Bryon D Johnson, Emilie Aschenbrenner, Timothy S Fenske, Mehdi Hamadani, Parameswaran Hari, Nirav N Shah> ;JAMA Oncology. 2022 May 1
33 citations
Efficacy of a third SARS-CoV-2 mRNA vaccine dose among hematopoietic cell transplantation, CAR T cell, and BiTE recipients.
Muhammad Bilal Abid, Micah Rubin, Nathan Ledeboer, Aniko Szabo, Walter Longo, Meera Mohan, Nirav N Shah, Timothy S Fenske, Sameem Abedin, Lyndsey Runaas, Anita D'Souza...> ;Cancer Cell. 2022 Apr 11
11 citations
Integrated safety analysis of umbralisib, a dual PI3Kδ/CK1ε inhibitor, in relapsed/refractory lymphoid malignancies.
Matthew S. Davids, Owen A. O'Connor, Wojciech Jurczak, Felipe Samaniego, Timothy S. Fenske, Pier Luigi Zinzani, Manish R. Patel, Nilanjan Ghosh, Bruce D. Cheson, Enric...> ;Blood Advances. 2021 Sep 21
21 citations
Early Relapse Identifies MCL patients with Inferior Survival after Intensive or Less Intensive Frontline Therapy.
David A. Bond, Jeffrey M. Switchenko, Diego Villa, Kami J. Maddocks, Michael C. Churnetski, Alina S. Gerrie, Subir Goyal, Krithika Shanmugasundaram, Oscar Calzada, Bha...> ;Blood Advances. 2021 Sep 13
7 citations
American Society of Transplantation and Cellular Therapy, Center of International Blood and Marrow Transplant Research, and European Society for Blood and Marrow Trans...
Pashna N. Munshi, Mehdi Hamadani, Ambuj Kumar, Peter Dreger, Jonathan W. Friedberg, Martin Dreyling, Brad S. Kahl, Mats Jerkeman, Mohamed A. Kharfan-Dabaja, Frederick ...> ;Transplantation and Cellular Therapy. 2021 Sep 1
17 citations
ASTCT, CIBMTR, and EBMT clinical practice recommendations for transplant and cellular therapies in mantle cell lymphoma
Pashna N. Munshi, Mehdi Hamadani, Ambuj Kumar, Peter Dreger, Jonathan W. Friedberg, Martin Dreyling, Brad S. Kahl, Mats Jerkeman, Mohamed A. Kharfan-Dabaja, Frederick ...> ;Bone Marrow Transplantation. 2021 Aug 20
89 citations
Response to SARS-CoV-2 vaccination in patients after hematopoietic cell transplantation and CAR-T cell therapy.
Binod Dhakal, Sameem Abedin, Timothy S. Fenske, Saurabh Chhabra, Nathan A. Ledeboer, Parameswaran Hari, Mehdi Hamadani> ;Blood. 2021 Oct 7
11 citations
Multi-Center Analysis of Practice Patterns and Outcomes of Younger and Older Patients with Mantle Cell Lymphoma in the Rituximab Era.
Reem Karmali, Jeffrey M. Switchenko, Subir Goyal, Krithika Shanmugasundaram, Michael C. Churnetski, Bhaskar Kolla, Veronika Bachanova, James N. Gerson, Stefan K. Barta...> ;American Journal of Hematology. 2021 Jul 29
Budesonide Prophylaxis Reduces the Risk of Engraftment Syndrome After Autologous Hematopoietic Cell Transplantation in Multiple Myeloma
Binod Dhakal, Bicky Thapa, Huaying Dong, Sergey Tarima, Saurabh Chhabra, Anita D'Souza, William R. Drobyski, Muhammad Bilal Abid, Nirav N. Shah, Timothy S. Fenske, Wal...> ;Clinical Lymphoma, Myeloma & Leukemia. 2021 Jun 18
3 citations
Intensive Induction Regimens after Deferring Initial Therapy for Mantle Cell Lymphoma Are Not Associated with Improved Survival
Krithika Shanmugasundaram, Subir Goyal, J. Switchenko, Oscar Calzada, Michael C. Churnetski, Bhaskar Kolla, Veronika Bachanova, James N. Gerson, Stefan K. Barta, Max J...> ;European Journal of Haematology. 2021 May 11
Join now to see all

Abstracts/Posters

Clinical Trial Participation Is Associated with Improved Overall Survival in Newly Diagnosed Patients with Mantle Cell Lymphoma
Timothy S. Fenske, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Short Time to Treatment Is Associated with Inferior Survival in Newly Diagnosed Patients with Mantle Cell Lymphoma
Timothy S. Fenske, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Fresh Versus Cryopreserved/Thawed Bispecific Anti-CD19/CD20 CAR-T Cells for Relapsed, Refractory Non-Hodgkin Lymphoma
Timothy S. Fenske, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Comparison of Reduced-Intensity Conditioning (RIC) Regimens for Allogeneic Hematopoietic Cell Transplantation (alloHCT) in Non-Hodgkin Lymphomas (NHL)-a Center for Int...
Timothy S. Fenske, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Comparison of Reduced-Intensity Conditioning (RIC) Regimens for Allogeneic Hematopoietic Cell Transplantation (alloHCT) for Classical Hodgkin Lymphoma (cHL):a Center f...
Timothy S. Fenske, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Does Addition of Rituximab (R) to BEAM Conditioning Improve Outcomes of Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Undergoing Autologous Hematopoietic Cell Tr...
Timothy S. Fenske, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Outcomes Following Early Relapse in Patients with Mantle Cell Lymphoma
Timothy S. Fenske, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Maintenance Rituximab Improves Outcomes in Mantle Cell Lymphoma Patients Who Respond to Induction Therapy with Bendamustine + Rituximab without Autologous Transplant
Timothy S. Fenske, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Join now to see all

Lectures

Five-Year Outcomes of SWOG S0: A Randomized Phase II US Intergroup Study of R-HCVAD Vs. R-Bendamustine Followed By Autologous Stem Cell Transplant for Patients with Ma...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018